This would also apply if calcification of soft tissues (e.g., ligaments) was directly related to excess FGF23 and its effect on target tissues, otherwise, if spinal stenosis is primarily related to osteoarthritis in the spine, it would likely not be amenable to treatment with burosumab. The gene discussed is FGF23; the disease is osteoarthritis.